Gainers Buzz: Gilead Sciences, Inc. (NASDAQ:GILD), Cemex SAB de CV (ADR ... Market News Call It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Should Investors Buy GILD After Yesterday's Slump? Find ... |
